Global Atopic Dermatitis (Atopic Eczema) Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Atopic dermatitis is also known as atopic eczema. Atopic dermatitis is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure and difficulties in permeability of skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis, including. The atopic dermatitis treatment includes mainly steroid creams and moisturizers. Often, antibiotics are used when there is a skin infection. Diagnosis is done by physical examination and in some cases, biopsy is performed. Treatment aims to control inflammation and relieving itching.
Global atopic dermatitis treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the atopic dermatitis treatment market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the atopic dermatitis treatment market during the forecast period.
Atopic dermatitis treatment market has been segmented on the basis of drug type, route of administration and distribution channel
Based on drug type, atopic dermatitis treatment market is segmented into
Geographically atopic dermatitis treatment market has been segmented into following regions Viz. North America, Latin America, Asia-Pacific, Europe, and Middle East &Africa. North America dominates atopic dermatitis treatment market, expected to show notable growth rates owing to product launches, lifestyle changes, and early treatment adoption. According to the national eczema association in the U.S., 31.6 million people are living with eczema. Europe atopic dermatitis treatment due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, availability of large patient pool and changing lifestyle.
Some of the market players in atopic dermatitis treatment market include Leo Pharma A/S (Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA) (Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland), Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few.
In March 2017, Dupixent(dupilumab), the first and only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis, approved by U.S. Food and Drug Administration (FDA). This drug was developed by Sanofi and Regeneron Pharmaceuticals in collaboration.
REPORT OUTLINE:
Global atopic dermatitis treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the atopic dermatitis treatment market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the atopic dermatitis treatment market during the forecast period.
Atopic dermatitis treatment market has been segmented on the basis of drug type, route of administration and distribution channel
Based on drug type, atopic dermatitis treatment market is segmented into
- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Phosphodiesterase type 4 (PDE-4) inhibitor
- Antibiotics
- Antihistamines
- Emollients
- Oral
- Topical
- Parenteral
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Geographically atopic dermatitis treatment market has been segmented into following regions Viz. North America, Latin America, Asia-Pacific, Europe, and Middle East &Africa. North America dominates atopic dermatitis treatment market, expected to show notable growth rates owing to product launches, lifestyle changes, and early treatment adoption. According to the national eczema association in the U.S., 31.6 million people are living with eczema. Europe atopic dermatitis treatment due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, availability of large patient pool and changing lifestyle.
Some of the market players in atopic dermatitis treatment market include Leo Pharma A/S (Denmark), Velite Pharmaceutical (India), Nestlé S.A. (Galderma SA) (Switzerland), Pfizer Inc. (U.S.), Anacor Pharmaceutical Inc. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S), Sanofi S.A. (France), Novartis AG (Switzerland), Bayer AG (Germany), Mylan N.V. (Meda Pharmaceuticals) (U.S.), Bristol-Myers Squibb (BMS) (U.S), and Allergan Plc. (Ireland) to name a few.
In March 2017, Dupixent(dupilumab), the first and only biologic medicine for the treatment of adults with moderate-to-severe atopic dermatitis, approved by U.S. Food and Drug Administration (FDA). This drug was developed by Sanofi and Regeneron Pharmaceuticals in collaboration.
REPORT OUTLINE:
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY
2. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET INTRODUCTION
2.1. Global Atopic Dermatitis Treatment Market– Taxonomy
2.2. Global Atopic Dermatitis Treatment Market–Definitions
2.2.1. Drug Type
2.2.2. Route of Administration
3. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Atopic Dermatitis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Atopic Dermatitis Treatment Market– Recent Market Introductions
4. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Corticosteroids
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Calcineurin Inhibitors
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immunosuppressants
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Antibiotics
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antihistamines
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Emollients
5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Oral
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Topical
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Parenteral
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.1.1. Corticosteroids
9.1.1.2. Calcineurin Inhibitors
9.1.1.3. Immunosuppressants
9.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
9.1.1.5. Antibiotics
9.1.1.6. Antihistamines
9.1.1.7. Emollients
9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Oral
9.1.2.2. Topical
9.1.2.3. Parenteral
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Online Pharmacies
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
9.1.6. North America Atopic Dermatitis Treatment Market Dynamics – Trends
10. EUROPE ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.1.1. Corticosteroids
10.1.1.2. Calcineurin Inhibitors
10.1.1.3. Immunosuppressants
10.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
10.1.1.5. Antibiotics
10.1.1.6. Antihistamines
10.1.1.7. Emollients
10.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Oral
10.1.2.2. Topical
10.1.2.3. Parenteral
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Online Pharmacies
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Atopic Dermatitis Treatment Market Dynamics – Trends
11. ASIA-PACIFIC ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.1.1. Corticosteroids
11.1.1.2. Calcineurin Inhibitors
11.1.1.3. Immunosuppressants
11.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
11.1.1.5. Antibiotics
11.1.1.6. Antihistamines
11.1.1.7. Emollients
11.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Oral
11.1.2.2. Topical
11.1.2.3. Parenteral
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Online Pharmacies
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
11.1.6. Asia-Pacific Atopic Dermatitis Treatment Market Dynamics – Trends
12. LATIN AMERICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.1.1. Corticosteroids
12.1.1.2. Calcineurin Inhibitors
12.1.1.3. Immunosuppressants
12.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
12.1.1.5. Antibiotics
12.1.1.6. Antihistamines
12.1.1.7. Emollients
12.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Oral
12.1.2.2. Topical
12.1.2.3. Parenteral
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Online Pharmacies
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Atopic Dermatitis Treatment Market Dynamics – Trends
13. MIDDLE EAST & AFRICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.1.1. Corticosteroids
13.1.1.2. Calcineurin Inhibitors
13.1.1.3. Immunosuppressants
13.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
13.1.1.5. Antibiotics
13.1.1.6. Antihistamines
13.1.1.7. Emollients
13.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Oral
13.1.2.2. Topical
13.1.2.3. Parenteral
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Online Pharmacies
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Atopic Dermatitis Treatment Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Leo Pharma A/S (Denmark)
14.2.2. Nestlé S.A. (Galderma SA) (Switzerland)
14.2.3. Pfizer Inc. (U.S.)
14.2.4. Anacor Pharmaceutical Inc. (U.S.)
14.2.5. Regeneron Pharmaceuticals, Inc. (U.S)
14.2.6. Sanofi S.A. (France)
14.2.7. Novartis AG (Switzerland)
14.2.8. Bayer AG (Germany)
14.2.9. Mylan N.V. (Meda Pharmaceuticals) (U.S.)
14.2.10. Bristol-Myers Squibb (BMS) (U.S)
14.2.11. Allergan Plc. (Ireland)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET INTRODUCTION
2.1. Global Atopic Dermatitis Treatment Market– Taxonomy
2.2. Global Atopic Dermatitis Treatment Market–Definitions
2.2.1. Drug Type
2.2.2. Route of Administration
3. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Atopic Dermatitis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Atopic Dermatitis Treatment Market– Recent Market Introductions
4. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Corticosteroids
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Calcineurin Inhibitors
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immunosuppressants
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Antibiotics
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antihistamines
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Emollients
5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Oral
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Topical
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Parenteral
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.1.1. Corticosteroids
9.1.1.2. Calcineurin Inhibitors
9.1.1.3. Immunosuppressants
9.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
9.1.1.5. Antibiotics
9.1.1.6. Antihistamines
9.1.1.7. Emollients
9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Oral
9.1.2.2. Topical
9.1.2.3. Parenteral
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Online Pharmacies
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
9.1.6. North America Atopic Dermatitis Treatment Market Dynamics – Trends
10. EUROPE ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.1.1. Corticosteroids
10.1.1.2. Calcineurin Inhibitors
10.1.1.3. Immunosuppressants
10.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
10.1.1.5. Antibiotics
10.1.1.6. Antihistamines
10.1.1.7. Emollients
10.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Oral
10.1.2.2. Topical
10.1.2.3. Parenteral
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Online Pharmacies
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Atopic Dermatitis Treatment Market Dynamics – Trends
11. ASIA-PACIFIC ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.1.1. Corticosteroids
11.1.1.2. Calcineurin Inhibitors
11.1.1.3. Immunosuppressants
11.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
11.1.1.5. Antibiotics
11.1.1.6. Antihistamines
11.1.1.7. Emollients
11.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Oral
11.1.2.2. Topical
11.1.2.3. Parenteral
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Online Pharmacies
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
11.1.6. Asia-Pacific Atopic Dermatitis Treatment Market Dynamics – Trends
12. LATIN AMERICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.1.1. Corticosteroids
12.1.1.2. Calcineurin Inhibitors
12.1.1.3. Immunosuppressants
12.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
12.1.1.5. Antibiotics
12.1.1.6. Antihistamines
12.1.1.7. Emollients
12.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Oral
12.1.2.2. Topical
12.1.2.3. Parenteral
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Online Pharmacies
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Atopic Dermatitis Treatment Market Dynamics – Trends
13. MIDDLE EAST & AFRICA ATOPIC DERMATITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.1.1. Corticosteroids
13.1.1.2. Calcineurin Inhibitors
13.1.1.3. Immunosuppressants
13.1.1.4. Phosphodiesterase type 4 (PDE-4) Inhibitors
13.1.1.5. Antibiotics
13.1.1.6. Antihistamines
13.1.1.7. Emollients
13.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Oral
13.1.2.2. Topical
13.1.2.3. Parenteral
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Online Pharmacies
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Atopic Dermatitis Treatment Market- Opportunity Analysis Index - By Route of Administration, By Drug Type, By Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Atopic Dermatitis Treatment Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Leo Pharma A/S (Denmark)
14.2.2. Nestlé S.A. (Galderma SA) (Switzerland)
14.2.3. Pfizer Inc. (U.S.)
14.2.4. Anacor Pharmaceutical Inc. (U.S.)
14.2.5. Regeneron Pharmaceuticals, Inc. (U.S)
14.2.6. Sanofi S.A. (France)
14.2.7. Novartis AG (Switzerland)
14.2.8. Bayer AG (Germany)
14.2.9. Mylan N.V. (Meda Pharmaceuticals) (U.S.)
14.2.10. Bristol-Myers Squibb (BMS) (U.S)
14.2.11. Allergan Plc. (Ireland)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS